SetPoint VNS — Responder Analysis

Thesis

The existing SetPoint mechanistic reference establishes why vagus nerve stimulation is the logical intervention for this patient’s documented vagal deficit. This document addresses a separate and complementary question: given everything documented about this patient’s physiological picture, pharmacological history, and current CNS status, what can be predicted — with appropriate epistemic humility — about how this system will respond to VNS, both therapeutically and adversely?

This is a single-case analytical projection. It cannot be validated against comparable cases because none exist in the literature. It is built from mechanistic reasoning, observed pharmacological patterns, and documented physiological findings. It does not attempt to predict outcome magnitude or draw conclusions about whether to proceed. It maps the terrain.

Two orientations structure the analysis. The first asks what factors predict strong positive response. The second asks what factors predict adverse or attenuated response. Each factor is examined on both sides without drawing conclusions. Interaction dynamics between factors are acknowledged but deferred — they represent a third analytical layer that requires the first two to be fully developed before the interactions can be mapped with any precision.

I. Factors Predicting Strong Positive Response

Ia. The Five-Factor Vagal Deficit as Amplified Opportunity

The existing SetPoint mechanistic reference documents five converging factors that have cumulatively reduced vagal anti-inflammatory tone across the lifespan: early antibiotic-induced microbiome disruption, ACE-related autonomic developmental impairment, prolonged unidentified pernicious anemia causing vagal demyelination, two ischemic strokes disrupting central autonomic regulation, and chronic inflammatory reflex fatigue from decades of severe active disease. Each factor independently reduces cholinergic anti-inflammatory output. Together they represent a cumulative deficit that has been running for decades.

A system running chronically below its anti-inflammatory capacity for that duration, through that many independent mechanisms, represents a larger gap between current output and potential output than a system with a single or recent deficit. VNS does not create new anti-inflammatory capacity — it substitutes for and supplements a pathway that exists but is underperforming. The greater the deficit, the greater the potential gain from restoring output.

The pressure test: is a larger deficit actually predictive of stronger response, or does it predict a system too compromised to respond adequately? The mechanistic argument favors response because VNS bypasses the damaged endogenous pathway entirely through direct electrical stimulation. It does not ask a compromised system to do more — it substitutes for the signal the system can no longer reliably generate itself. The degree of endogenous deficit is therefore less relevant to response potential than it would be for an intervention that required the endogenous pathway to be partially functional. The one genuine caveat connects to the demyelination factor in Section II — if the efferent pathway itself is compromised, the substitution argument has limits. That is a Section II consideration.

Ib. Pharmacological Phenotype Split as Predictor of Strong Positive Response

The observation is documented and precise: the two biologics that reached central and autonomic signaling territory produced immediate strong neurological responses. The two that stayed in the peripheral inflammatory compartment produced nothing. The pattern is binary and has held across mechanistically unrelated drugs over more than a decade: drugs either produce no engagement whatsoever — no benefit, no reaction — or they produce immediate, amplified neurological responses that exceed clinical expectations. There is no middle ground. No drug has produced a modest, proportionate, or gradual response.

The argument for positive response: VNS operates entirely in the central and autonomic territory. It delivers a direct electrical signal to a nerve whose primary function is autonomic regulation. If this system is demonstrably highly responsive to interventions that reach that territory, the same sensitivity predicts strong engagement with a direct autonomic intervention.

The pressure test: Actemra and Orencia produced adverse neurological reactions, not therapeutic benefit. The pharmacological phenotype split demonstrates strong central and autonomic reactivity — but the observed reactions were adverse, not therapeutic. Are we justified in predicting that the same reactivity produces therapeutic benefit from VNS?

The distinction that makes this argument hold is the directionality of the intervention. Actemra and Orencia perturbed central signaling in ways the compromised nervous system could not handle — blocking or modulating pathways that then expressed disproportionately. VNS reinforces a pathway that is supposed to be active but is not performing adequately. The reactivity is the same; the direction of the perturbation is different.

The compensatory equilibrium insight deepens this argument further. A system that has reorganized around its own dysfunction over decades is particularly vulnerable to high-specificity molecular perturbation of individual components — and particularly well-suited to an intervention that works with rather than against that reorganization. VNS does not target a component of the compensatory architecture. It reinforces the regulatory pathway that the entire architecture is organized around.

That distinction is the load-bearing element of this argument. It is mechanistically coherent but it is an inference — we are predicting that the same sensitivity that produced adverse reactions to foreign molecular signals will produce therapeutic amplification when the signal is native to the system’s own architecture.

Ic. Biologic Failure Pattern as Indirect Evidence

The standard interpretation of TNF inhibitor failure across two drugs and more than two years is treatment-refractory disease. The mechanistic interpretation is more specific: blocking one downstream cytokine product while leaving the upstream NF-κB drive fully intact is insufficient. The LPS/TLR4/NF-κB pathway drives the entire cytokine cluster simultaneously. Single-target blockade downstream of that drive removes one output while the engine continues running at full capacity producing everything else.

VNS intervenes at the transcription level — upstream of cytokine production entirely. It suppresses NF-κB activity through the cholinergic pathway, reducing transcription of TNF, IL-1β, IL-6, IL-18, and HMGB1 simultaneously. It is not competing with an upstream driver the way a biologic competes with a single downstream product. It is addressing the transcription machinery itself.

The pressure test: does TNF inhibitor failure actually tell us anything useful about VNS response, or are these interventions so mechanistically different that the failure is simply irrelevant rather than indirectly supportive? The honest answer is that biologic failure is neutral with respect to VNS — it neither predicts success nor failure. The indirect support argument is that the failure pattern is consistent with a system whose inflammatory drive operates upstream of where biologics intervene, which is exactly where VNS operates. That is suggestive but not predictive.

Id. HMGB1 as Unaddressed Late-Phase Disease Driver

HMGB1 is a late-phase alarmin — a danger signal released hours to days after initial inflammatory activation, long after triggering cytokines have peaked. It sustains the inflammatory state independently, drives synovial fibroblast activation, and maintains tissue destruction even when acute cytokine levels are modulated. It is not TNF, it is not IL-6, and it has not been addressed by any biologic that has been tried.

The cholinergic anti-inflammatory pathway specifically suppresses HMGB1 release. This is one of the most well-characterized effects of vagal stimulation — the original research establishing the cholinergic anti-inflammatory pathway identified HMGB1 suppression as a primary mechanism. VNS reaches something that has been driving disease activity throughout the entire biologic trial period without ever being touched.

The argument for positive response: if HMGB1 has been an unaddressed component of disease activity throughout, suppressing it through VNS removes a driver that has never been targeted. The therapeutic contribution of that suppression is unknown in magnitude but mechanistically real.

The pressure test: there is no direct evidence that HMGB1 is elevated or pathologically active in this patient. Its involvement is inferred from the disease pattern and the known biology of longstanding severe RA with continuous inflammatory drive. That inference is reasonable but it is an inference.

Ie. Natural Intervention Tolerance as Predictor

The observed pattern: across years of managing a complex multi-system condition, interventions that work with existing physiological architecture — helminthic therapy, betaine HCl, nutritional supplementation, digestive enzymes — have been tolerated without the amplification reactions that pharmaceuticals consistently produce. The sensitization threshold that pharmaceuticals cross repeatedly has never been approached by natural or physiological interventions.

The deeper mechanistic explanation for this pattern goes beyond diffuse versus targeted signaling. A system that has been chronically dysregulated for decades does not simply have elevated inflammatory markers — it reorganizes itself around those elevations. Thrombocytosis, elevated IgA, persistent RF, the entire laboratory pattern — these are not purely pathological. They represent a compensatory architecture the system has constructed under duress, with multiple components partially ameliorating each other in ways that are largely unmapped. High-specificity pharmaceutical intervention targeting a single component of that architecture does not just reduce one signal — it destabilizes a finely balanced compensatory equilibrium. The amplification reactions and permanent damage that have followed pharmaceutical exposures may reflect this destabilization as much as receptor sensitivity alone.

Natural and physiological interventions have not triggered this response because they work with the compensatory architecture rather than targeting specific components of it.

The argument for positive response: VNS is categorically aligned with the class of interventions this system has tolerated. It delivers a signal native to the system’s own neural architecture, reinforces an existing pathway rather than blocking or modulating a specific component, and does not introduce a targeted molecular perturbation into a finely balanced compensatory system. It is the least disruptive class of intervention available for the target mechanism.

The pressure test: electrical stimulation is novel input to the nervous system even if it works with existing architecture. The tolerance of natural interventions may not fully transfer. And we cannot know in advance whether VNS stimulation at therapeutic parameters will interact with the compensatory architecture in ways we cannot predict. That uncertainty is real and is carried forward into the interaction dynamics section.

If. Reset Dynamic and VNS as Continuous Regulatory Tone

This system has a specific inflammatory dynamic that goes beyond elevated continuous baseline. Inflammation builds momentum — accumulates, escalates, and can be interrupted. Certain interventions have produced durable resets: prednisone most powerfully, producing a hard system reset from which the inflammatory trajectory restarts from a new lower baseline and takes considerable time to rebuild. Ibuprofen, hydroxychloroquine, and tramadol produced softer versions of the same dynamic — interrupting inflammatory momentum and producing durable resets that outlasted the drug’s active pharmacological window by days to weeks. None of these drugs are classified as anti-inflammatories. Their reset effect in this system is an expression of the upstream regulatory signal amplification pattern — each touched autonomic or immune regulatory pathways and the system responded with primary anti-inflammatory effect disproportionate to the drug’s primary classification.

Helminthic therapy at peak efficacy operated similarly, though through a different mechanism — not discrete resets but sustained regulatory tone that prevented inflammatory momentum from building in the first place. The post-2024 dysbiosis event reduced HT efficacy substantially; the worms are still present and necessary but the sustained regulatory tone they previously maintained has been lost.

VNS as continuous cholinergic anti-inflammatory stimulation may function as exactly the sustained regulatory presence that prevents inflammatory momentum from building — the thing HT used to do more effectively, and that prednisone could do acutely but with serious cumulative consequences. This is not a mechanism VNS is designed around in the standard clinical framing. But in a system with this specific inflammatory dynamic, continuous vagal tone may be precisely what the system needs and has been unable to generate endogenously.

This is potentially the most mechanistically apt argument for VNS in this specific patient — not just that it addresses the vagal deficit, but that it may restore the regulatory tone that has been the missing element in this system’s ability to prevent inflammatory escalation.

The pressure test: this argument rests on the inference that VNS continuous stimulation functions like the sustained regulatory tone HT provided at its most effective. HT works through immune retraining and mucosal modulation; VNS works through direct cholinergic pathway activation. These are parallel but distinct mechanisms. Whether VNS produces the same sustained momentum-prevention effect is an inference, not an established prediction.

II. Factors Predicting Adverse or Attenuated Response

IIa. Encephalomalacia

The July 2025 MRI with contrast confirmed permanent structural tissue loss — encephalomalacia — in the right insula posteriorly, corresponding to the 2018 infarct site. This is not a functional deficit inferred from symptoms. It is confirmed absence of tissue at a specific anatomical location that is central to the VNS question.

The right insula is a primary site of autonomic signal integration. It processes interoceptive information, modulates autonomic output, and participates in central regulation of the inflammatory reflex. VNS generates signals that travel from the vagus nerve through the brainstem and into higher cortical centers including the insula for integration and modulation. The brainstem nuclei that mediate the cholinergic anti-inflammatory reflex arc are intact — the therapeutic effect does not require intact insular cortex to function at that level. The unknown is what happens to signal processing and integration above the brainstem when the primary cortical integration site is structurally damaged. Three possibilities exist: the damage is functionally irrelevant to VNS response because the therapeutic arc operates below the level of insular processing; the damage attenuates or modifies how VNS signals are integrated at higher levels without blocking the therapeutic effect; or the damage produces aberrant signal processing in ways that are not predictable from current knowledge. There is no literature on VNS in patients with confirmed insular encephalomalacia. This is genuinely unknown territory.

The more serious concern is that the encephalomalacia is not a fixed historical finding — it is a point on a documented progressive trajectory. Small vessel CNS disease has been confirmed on serial imaging across four time points spanning nine years, with each imaging series showing progression. The functional correlates of that progression are actively worsening in real time. Following the 2024 B12 gap, a crisis developed that resolved but left a permanently higher B12 requirement — from once weekly to twice weekly methylcobalamin. Following the HCQ vestibular crisis in late 2025, the requirement escalated to daily injections, and even that is now insufficient. Proprioceptive function is deteriorating — maintaining balance requires increasing conscious effort and compensation, with intermittent gait abnormality. This is not a stable system with historical damage. It is a system in active functional decline in the specific domain — autonomic and vestibular integration — that VNS most directly touches. The question is therefore not only how existing structural damage affects VNS signal processing, but whether ongoing deterioration at the primary autonomic integration site changes VNS candidacy in a more fundamental way.

The conditional mitigating factor is the APS diagnostic and treatment pathway currently in process through Barrow. If antiphospholipid syndrome is confirmed and anticoagulation is initiated, the mechanism driving progressive small vessel CNS disease may be directly addressed. Existing structural damage — the encephalomalacia — is permanent and will not reverse. But the vasculopathic process producing ongoing deterioration could be arrested or substantially slowed. Concurrently, the proprioceptive and vestibular functional decline may reflect two converging processes: ongoing small vessel ischemic damage from the unaddressed vasculopathy, and demyelination from B12 insufficiency relative to current neurological demand. APS treatment addresses the first; optimized B12 management addresses the second. If both drivers can be stabilized, the trajectory changes even if existing damage cannot be undone. This reframes the encephalomalacia factor from a static concern about permanent damage to a dynamic question about whether the underlying driver of ongoing deterioration can be addressed — and the answer may be yes, through a treatment path already in progress. The implications for VNS timing are developed in Section III.

IIb. Demyelination

The concern is specific and mechanistic: vagal signal propagation depends on intact myelin. The vagus is the longest autonomic nerve in the body and has substantial myelin requirements. Prolonged B12 deficiency — confirmed positive in 2018 with no action taken, confirmed again in 2023 with inadequate treatment initiated — produced demyelination of unknown extent and duration across vagal, cerebellar, and vestibular pathways before any repletion began.

The therapeutic question is whether demyelination attenuates the signal VNS delivers. If the efferent vagal pathway carries a degraded signal due to reduced conduction velocity and fidelity, the cholinergic anti-inflammatory arc may be activated less efficiently than in a patient with intact myelin. The practical risk is that stimulation parameters are increased to compensate for attenuated signal propagation — raising adverse effect risk without proportional therapeutic benefit.

B12 is now optimized on daily methylcobalamin injections and remyelination is ongoing. The complication is that remyelination is slow, is not measurable by any currently applied test in this patient, and is occurring in a system simultaneously sustaining ongoing small vessel ischemic damage that may be counteracting remyelination gains. The net current state of vagal myelin integrity is genuinely unknown.

The functional picture adds a more serious layer. The escalating B12 requirement — from once weekly to twice weekly to daily, with daily now insufficient — suggests that neurological demand is outpacing repletion capacity. This is not a stable remyelination trajectory. It is a system where the deficit may be expanding faster than it is being addressed.

The pressure test: demyelination is not binary. Partial demyelination produces partial signal attenuation, not signal absence. VNS has produced meaningful responses in patients with various degrees of neural compromise. The question is not whether demyelination forecloses VNS response but whether it attenuates it to a degree that affects therapeutic adequacy — and that cannot be determined without stimulation.

As with Section IIa, the APS treatment pathway is conditionally relevant. If the vasculopathic process driving ongoing small vessel damage is arrested, the counterforce working against remyelination is reduced. The demyelination concern is most serious in a system where the damage is actively expanding. In a stabilized system, remyelination with optimized B12 becomes a more viable trajectory.

IIc. Amplification Pattern as Liability

The same pharmacological phenotype that appears in Section Ib as a predictor of strong positive response reappears here as a liability. The pattern is bidirectional and the same mechanism drives both directions.

VNS produces known adverse effects during titration: voice change, cough, throat sensations, cardiac rate effects, and in some patients dizziness and balance disturbance. In a typical patient these are dose-dependent, manageable, and resolve with parameter adjustment. Standard titration protocols are designed around typical nervous system responses to incrementally increasing stimulation.

This patient’s nervous system does not respond typically. The documented pattern is immediate, amplified engagement when a threshold is crossed — not a gradual proportionate response that allows incremental adjustment. HCQ produced a vestibular crisis within days of daily dosing. Actemra produced numbness and burning rapidly. Orencia produced immediate sensory phenomena after one or two infusions. Methotrexate produced catastrophic neurological and psychiatric effects within days of the first dose. In each case the reaction was fast, disproportionate to the exposure, and in several cases permanent.

The titration assumption underlying standard VNS protocols is that adverse effects appear gradually and provide warning before becoming serious. That assumption may not hold in this system. The threshold between tolerable and disproportionate reaction has been crossed rapidly and without warning across multiple drug classes.

A critical refinement to this picture: the reactions that produced permanent damage all occurred under conditions of continuous or daily exposure. PRN use of the same drugs — HCQ, ibuprofen, tramadol — was tolerated for extended periods, often producing amplified therapeutic benefit without sensitization. The pattern is not simply amplified reaction to any exposure. It is amplified reaction specifically when continuous exposure crosses a threshold the system cannot accommodate.

VNS is by design a continuous intervention. The PRN management strategy that has allowed this patient to utilize amplified therapeutic benefits while avoiding sensitization reactions is not available with an implanted device. This is the specific VNS-relevant risk within the amplification pattern — not that any reaction will be amplified, but that continuous stimulation eliminates the management approach that has kept the amplification pattern on the therapeutic side of the threshold throughout the pharmacological history.

An additional layer: the tramadol story may not be pure sensitization. After approximately a decade of daily low-dose use, migraine-level headaches developed at daily frequency. That threshold crossing may reflect the system itself changing — ongoing neurological deterioration reaching a point where the serotonergic load that was previously tolerable became intolerable. If so, the continuous exposure risk from VNS is compounded by the fact that the system is not static. It is actively deteriorating in the relevant domain, which means thresholds that might be tolerable initially could be crossed by system change rather than by stimulation change.

The compensatory equilibrium insight applies here as well. Continuous VNS stimulation enters a finely adapted system that has reorganized around its dysfunction. Whether that stimulation works with or against the compensatory architecture cannot be predicted from drug response patterns alone, because VNS is not a drug. This uncertainty is carried forward to the interaction dynamics section.

The most serious specific risk given the current baseline is balance and vestibular disturbance — a documented standard VNS adverse effect. In a patient whose vestibular and proprioceptive baseline is already compromised, actively deteriorating, and has shown a pattern of permanent rather than reversible damage from each additional insult, a titration-phase vestibular adverse effect carries a different risk profile than it would in a typical patient.

The pressure test: the amplification pattern has been observed with pharmacological agents introducing foreign molecular signals. VNS is not a foreign molecular signal. The argument from Section Ib — that native architecture signals may behave differently — applies here too. It is possible that the amplification tendency is specific to high-specificity receptor perturbation and does not extend to direct neural stimulation. That is the load-bearing uncertainty in this section and it cannot be resolved without stimulation.

IId. Compromised CNS Baseline and Recent Insult

The baseline entering any VNS candidacy evaluation is not a stable chronic state. It is the product of cumulative discrete insults, each reducing reserve, with the most recent and most severe occurring months ago.

The documented insult sequence relevant to current baseline: two cryptogenic ischemic strokes 2016 and 2018, with confirmed permanent structural damage at the right insula. Progressive small vessel CNS disease across four imaging time points. Hydroxychloroquine vestibular crisis late 2025 into early 2026, producing permanent vestibular and balance damage with residual deficits that have not resolved. A recent acute neurological escalation — cognitive fog, executive function loss, word retrieval failure, proprioceptive disturbance requiring conscious compensation, anxiety and overwhelm with autonomic and limbic character — requiring prednisone intervention with residual deficits persisting after partial resolution.

Each insult has reduced the baseline. Each recovery has been to a lower functional level than the one before. The trajectory is documented and consistent.

An important dimension of this picture: high cognitive reserve has masked the functional losses from clinical view throughout this history. The 2017 neuropsychological evaluation documented exceptional baseline — Full Scale IQ 126, Verbal Comprehension 132, Working Memory 131. Compensation at that cognitive level makes deficits invisible against population norms. Strokes that would have produced visible sequelae in most patients produced none that were clinically apparent. The current cognitive and neurological decline is real and functionally significant, but it remains partially masked by the same reserve that made prior losses invisible. A current neuropsychological evaluation compared against the 2017 individual baseline — not population norms — would reveal losses that the clinical picture currently underrepresents.

The specific concern for VNS is that titration introduces stimulation into a system that is not stable. The system is still absorbing the HCQ crisis. The recent acute escalation has not fully resolved. The proprioceptive and vestibular deterioration is active and worsening. Standard VNS titration assumptions are built around a stable if compromised baseline. This patient’s nervous system is in active flux.

The risk is not simply that adverse effects could occur. It is that adverse effects occurring in a system already in active deterioration, with a documented pattern of permanent rather than reversible neurological outcomes, could accelerate a trajectory that is already moving in a concerning direction. There is no buffer. The margin between current functional status and serious functional compromise is narrower than it has ever been.

The conditional mitigating factor developed in Section IIa applies here with equal force. If APS is confirmed and anticoagulation initiated, the vasculopathic driver of ongoing deterioration may be arrested. A system that has stabilized after treatment of its underlying vasculopathy is a meaningfully different candidate than a system still in active deterioration. The implications for timing are developed in Section III.

III. Timing and Readiness Considerations

This section does not ask whether VNS is the right intervention. It asks what factors are relevant to timing — recognizing that delay has real costs and that waiting for ideal conditions is not a realistic option.

The current moment is characterized by conditions that are analytically relevant to timing without being determinative.

The system is still absorbing the HCQ vestibular crisis. The most recent major neurological insult occurred months ago. Permanent residual damage is confirmed. Whether the full consequences of that insult have declared themselves is not yet clear.

The APS diagnostic and treatment pathway is active but unresolved. If APS is confirmed and anticoagulation initiated, the underlying vasculopathic driver of progressive CNS deterioration may be addressed. This would represent a change in the physiological terrain — not symptom management but potential stabilization of the mechanism driving ongoing damage. Anticoagulation works relatively quickly in terms of its primary prothrombotic mechanism. Whether it stabilizes the progressive small vessel disease would become observable over time, and would be relevant to VNS candidacy and response prediction.

The recent acute neurological escalation has not fully resolved. Residual proprioceptive deficits and word retrieval impairment persist.

The counter-argument to any delay is equally real and must be carried with equal weight. Structural joint destruction is accelerating. Tendons are torn. Bone is eroding. The inflammatory load that VNS would address is active and causing irreversible damage now. Every month of delay is a month of continued destruction that cannot be recovered. The ongoing functional decline in mobility, hand function, and neurological status is not abstract — it is the lived daily reality documented in this record.

Timing is not a question this document can resolve. It requires weighing ongoing inflammatory damage against the considerations above, in the context of a patient who is not a research subject waiting for data and who has both the analytical capacity and the right to make informed decisions about her own care under real-world constraints.

IV. Factors With Indeterminate Outcome

The gut barrier dysfunction and continuous LPS translocation maintain persistent TLR4 stimulation and NF-κB activation as a baseline condition. VNS suppresses NF-κB driven cytokine transcription through the cholinergic pathway. These two mechanisms operate on the same transcription machinery from opposite directions simultaneously — one continuously activating, one episodically suppressing.

The question is what happens at that intersection. Several outcomes are conceivable: VNS suppression could meaningfully reduce cytokine output even against a continuous upstream driver, producing net therapeutic benefit; the continuous upstream driver could substantially limit VNS suppression, producing attenuated benefit; the two forces could interact in non-linear ways not predictable from either mechanism independently; or VNS could partially address gut barrier dysfunction itself through vagal modulation of intestinal permeability, an effect with some supporting evidence that would represent an unexpected additional benefit.

None of these can be predicted with confidence. The interaction is real. The direction and magnitude are unknown. It is noted here because ignoring it would be analytically incomplete. It may become more resolvable as the gut barrier situation evolves through interventions currently under consideration.

V. Interaction Dynamics

Explicitly deferred. The factors in Sections I and II do not operate independently. Their interactions may be the most analytically significant territory in this document. That layer requires Sections I through IV to be fully developed and pressure-tested before the interactions can be mapped with any analytical rigor. Reserved for future development.

Integrated Constitutional Systems Model:
This document reflects current systems-level interpretation, mechanistic analysis, and working hypotheses based on documented history, longitudinal patterns, imaging, laboratory findings, and current research.
It is a thinking and synthesis tool, not a clinical record or formal medical conclusion.

Cross-References

The following documents are part of the master reference system and should be read alongside this document:

• Constitutional CNS Document — the CNS system and its coupling with the gut picture
• Iron Dysbiosis Reference — the iron trigger, collapse mechanism, locked state evidence, personal statement
• Vagal Tone Deficit Mechanistic Reference — the gut-vagus connection in detail, five-factor cumulative vagal deficit
• SetPoint VNS Responder Analysis — Assessment based on truly unknowable response in this system
• Helminthic Therapy Reference — current intervention status and relationship to the gut picture
• Pharmacological Phenotype — amplified medication response pattern, sensitization threshold, PRN constraint, permanently foreclosed agents, clinical safety implications
• Neurological Pattern Reference — HPA axis dysregulation as possible CNS-origin downstream consequence

This document reflects mechanistic relationships and personal hypotheses based on documented history and current research. It is a thinking tool, not a clinical record. 20260520